{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:45:47Z","timestamp":1792511147841,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T00:00:00Z","timestamp":1654128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T00:00:00Z","timestamp":1654128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100015283","name":"Bloomberg Philanthropies","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015283","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Until recently, few carceral facilities offered medications for opioid use disorder (MOUD). Although more facilities are adopting MOUD, much remains to be learned about addressing implementation challenges related to expansion of MOUD in carceral settings and linkage to care upon re-entry. This is particularly important in jails, where individuals cycle rapidly in and out of these facilities, especially in jurisdictions beginning to implement bail reform laws (i.e., laws that remove the requirement to pay bail for most individuals). Increasing access to MOUD in these settings is a key unexplored challenge.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this qualitative study, we interviewed staff from county jails across New Jersey, a state that has implemented state-wide efforts to increase capacity for MOUD treatment in jails. We analyzed themes related to current practices used to engage individuals in MOUD while in jail and upon re-entry; major challenges to delivering MOUD and re-entry services, particularly under bail reform conditions; and innovative strategies to facilitate delivery of these services.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Jail staff from 11 New Jersey county jails participated in a baseline survey and an in-depth qualitative interview from January\u2013September 2020. Responses revealed that practices for delivering MOUD varied substantially across jails. Primary challenges included jails\u2019 limited resources and highly regulated operations, the chaotic nature of short jail stays, and concerns regarding limited MOUD and resources in the community. Still, jail staff identified multiple facilitators and creative solutions for delivering MOUD in the face of these obstacles, including opportunities brought on by the COVID-19 pandemic.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Despite challenges to the delivery of MOUD, states can make concerted and sustained efforts to support opioid addiction treatment in jails. Increased use of evidence-based clinical guidelines, greater investment in resources, and increased partnerships with health and social service providers can greatly improve reach of treatment and save lives.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13722-022-00313-6","type":"journal-article","created":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T14:02:54Z","timestamp":1654178574000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Jail-based treatment for opioid use disorder in the era of bail reform: a qualitative study of barriers and facilitators to implementation of a state-wide medication treatment initiative"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7396-3938","authenticated-orcid":false,"given":"Noa","family":"Krawczyk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachini","family":"Bandara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney","family":"Merritt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hridika","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"McEntee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Schiff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. Jia","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Whaley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Latimore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Saloner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,2]]},"reference":[{"issue":"3","key":"313_CR1","doi-asserted-by":"publisher","first-page":"e180558","DOI":"10.1001\/jamanetworkopen.2018.0558","volume":"1","author":"TNA Winkelman","year":"2018","unstructured":"Winkelman TNA, Chang VW, Binswanger IA. Health, polysubstance use, and criminal justice involvement among adults with varying levels of opioid use. JAMA Netw Open. 2018;1(3):e180558. https:\/\/doi.org\/10.1001\/jamanetworkopen.2018.0558.","journal-title":"JAMA Netw Open"},{"key":"313_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.107997","author":"N Krawczyk","year":"2020","unstructured":"Krawczyk N, Schneider KE, Eisenberg M, Richards TM, Ferris L, Mojtabai R, et al. Opioid overdose death following criminal justice involvement: linking statewide corrections and hospital databases to detect individuals at highest risk. Drug Alcohol Depend. 2020. https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.107997.","journal-title":"Drug Alcohol Depend"},{"issue":"9","key":"313_CR3","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1111\/j.1360-0443.2010.02990.x","volume":"105","author":"ELC Merrall","year":"2010","unstructured":"Merrall ELC, Kariminia A, Binswanger IA, Hobbs MS, Farrell M, Marsden J, et al. Meta-analysis of drug\u2010related deaths soon after release from prison. Addiction. 2010;105(9):1545\u201354.","journal-title":"Addiction"},{"issue":"2","key":"313_CR4","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1056\/NEJMsa064115","volume":"356","author":"IA Binswanger","year":"2007","unstructured":"Binswanger IA, Stern MF, Deyo RA, Heagerty PJ, Cheadle A, Elmore JG, et al. Release from prison\u2014a high risk of death for former inmates. N Engl J Med. 2007;356(2):157\u201365.","journal-title":"N Engl J Med"},{"key":"313_CR5","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.drugalcdep.2018.04.034","volume":"189","author":"LN Pizzicato","year":"2018","unstructured":"Pizzicato LN, Drake R, Domer-Shank R, Johnson CC, Viner KM. Beyond the walls: risk factors for overdose mortality following release from the Philadelphia Department of Prisons. Drug Alcohol Depend. 2018;189:108\u201315.","journal-title":"Drug Alcohol Depend."},{"issue":"1","key":"313_CR6","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.drugalcdep.2009.06.015","volume":"105","author":"A Nunn","year":"2009","unstructured":"Nunn A, Zaller N, Dickman S, Trimbur C, Nijhawan A, Rich JD. Methadone and buprenorphine prescribing and referral practices in US prison systems: results from a nationwide survey. Drug Alcohol Depend. 2009;105(1):83\u20138.","journal-title":"Drug Alcohol Depend"},{"key":"313_CR7","unstructured":"Lopez G. How America\u2019s prisons are fueling the opioid epidemic. Vox. 2018. https:\/\/www.vox.com\/policy-and-politics\/2018\/3\/13\/17020002\/prison-opioid-epidemic-medications-addiction."},{"issue":"2","key":"313_CR8","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1177\/1078345816634079","volume":"22","author":"SV Aronowitz","year":"2016","unstructured":"Aronowitz SV, Laurent J. Screaming behind a door: the experiences of individuals incarcerated without medication-assisted treatment. J Correct Health Care. 2016;22(2):98\u2013108.","journal-title":"J Correct Health Care"},{"issue":"12","key":"313_CR9","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1377\/hlthaff.2017.0890","volume":"36","author":"N Krawczyk","year":"2017","unstructured":"Krawczyk N, Picher CE, Feder KA, Saloner B. Only one in twenty justice-referred adults in specialty treatment for opioid use receive methadone or buprenorphine. Health Aff (Millwood). 2017;36(12):2046\u201353.","journal-title":"Health Aff (Millwood)"},{"key":"313_CR10","volume-title":"Opioid use disorder treatment in jails and prisons","author":"Pew Charitable Trusts","year":"2020","unstructured":"Pew Charitable Trusts. Opioid use disorder treatment in jails and prisons. Berlin: Pew Charitable Trusts; 2020."},{"key":"313_CR11","unstructured":"Marton A, de la Gu\u00e9ronni\u00e8re G. Presentation on court actions: recent court actions impacting the substance use disorder field. 2019.\u00a0http:\/\/nasadad.org\/wp-content\/uploads\/2019\/06\/6.6.19-Recent-Court-Actions-Impacting-SUD-Field.pdf.\u00a0Accessed 18\u00a0Feb 2021."},{"issue":"4","key":"313_CR12","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1001\/jamapsychiatry.2017.4614","volume":"75","author":"TC Green","year":"2018","unstructured":"Green TC, Clarke J, Brinkley-Rubinstein L, Marshall BDL, Alexander-Scott N, Boss R, et al. Postincarceration fatal overdoses after implementing medications for addiction treatment in a statewide correctional system. JAMA Psychiatry. 2018;75(4):405\u20137. https:\/\/doi.org\/10.1001\/jamapsychiatry.2017.4614.","journal-title":"JAMA Psychiatry"},{"key":"313_CR13","doi-asserted-by":"publisher","first-page":"3473","DOI":"10.1111\/add.15565","volume":"116","author":"S Bandara","year":"2021","unstructured":"Bandara S, Kennedy-Hendricks A, Merritt S, Barry CL, Saloner B. Methadone and buprenorphine treatment in united states jails and prisons: lessons from early adopters. Addiction. 2021;116:3473\u201381.","journal-title":"Addiction."},{"key":"313_CR14","unstructured":"New Jersey Overdose Data Dashboard. Drug-Related Deaths. New Jersey Department of Health. 2020.\u00a0https:\/\/www.state.nj.us\/health\/populationhealth\/opioid\/opioid_deaths.shtml.\u00a0Accessed 22\u00a0Jan 2021."},{"key":"313_CR15","unstructured":"ACLU New Jersey. Pretrial justice reform in New Jersey is working, new data show. 2020.\u00a0https:\/\/www.aclu-nj.org\/theissues\/criminaljustice\/pretrial-justice-reform. Accessed 11\u00a0Jan 2021."},{"key":"313_CR16","unstructured":"Zeng Z. Jail Inmates in 2018. Bur Justice Stat. 2020.\u00a0https:\/\/www.bjs.gov\/content\/pub\/pdf\/ji16.pdf. Accessed 18 Feb 2021."},{"key":"313_CR17","unstructured":"The Marshall Project. The System: The State of Bail Reform. 2020. https:\/\/www.themarshallproject.org\/2020\/10\/30\/the-state-of-bail-reform. Accessed 22 Jan 2021."},{"key":"313_CR18","unstructured":"Joe Biden\u2019s Criminal Justice Policy. Joe Biden. https:\/\/joebiden.com\/justice\/#. Accessed 22 Jan 2021."},{"key":"313_CR19","unstructured":"Hunter L. What you need to know about ending cash bail. Center for American Progress. 2020.\u00a0https:\/\/www.americanprogress.org\/issues\/criminal-justice\/reports\/2020\/03\/16\/481543\/ending-cash-bail\/. Accessed 11\u00a0Jan 2021."},{"key":"313_CR20","unstructured":"Grant GA. Report to the Governor and the Legislature Acting Administrative Director of the Courts. 2018."},{"issue":"6","key":"313_CR21","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","volume":"19","author":"A Tong","year":"2007","unstructured":"Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health care J Int Soc Qual Health Care. 2007;19(6):349\u201357.","journal-title":"Int J Qual Health care J Int Soc Qual Health Care"},{"key":"313_CR22","unstructured":"SocioCultural RConsultantsL Dedoose Version 8.0.35, web application for managing, analyzing, and presenting qualitative and mixed method research data. Los Angeles, CA: SocioCultural Research Consultants, LLC; 2018.\u00a0https:\/\/www.dedoose.com\/userguide\/appendix. Accessed 15\u00a0Jan 2021."},{"issue":"1","key":"313_CR23","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1177\/160940690600500107","volume":"5","author":"J Fereday","year":"2006","unstructured":"Fereday J, Muir-Cochrane E. Demonstrating rigor using thematic analysis: a hybrid approach of inductive and deductive coding and theme development. Int J Qual Methods. 2006;5(1):80\u201392. https:\/\/doi.org\/10.1177\/160940690600500107.","journal-title":"Int J Qual Methods"},{"key":"313_CR24","doi-asserted-by":"crossref","unstructured":"McDonald N, Schoenebeck S, Forte A. Reliability and inter-rater reliability in qualitative research: norms and guidelines for CSCW and HCI practice. In: Proceedings of the ACM on human-computer interaction, Vol.\u00a03. 2019. p.\u00a023.","DOI":"10.1145\/3359174"},{"key":"313_CR25","doi-asserted-by":"crossref","unstructured":"Braun V, Clarke V. Thematic analysis. In: APA handbook of research methods in psychology, Vol 2: Research designs: quantitative, qualitative, neuropsychological, and biological. American Psychological Association; 2012. pp.\u00a057\u201371. \/record\/2011-23864-004. Accessed\u00a010 Sept 2020.","DOI":"10.1037\/13620-004"},{"key":"313_CR26","unstructured":"SAMHSA. TIP 63. Medications for opioid use disorder. 2019.\u00a0https:\/\/store.samhsa.gov\/product\/TIP-63-Medications-for-Opioid-Use-Disorder-Full-Document-Including-Executive-Summary-and-Parts-1-5-\/SMA19-5063FULLDOC. Accessed 26\u00a0Nov 2019."},{"key":"313_CR27","unstructured":"SAMHSA. Federal Guidelines for Opioid Treatment Programs | SAMHSA Publications and Digital Products [Internet]. Rockville MD. 2015 [cited 2021 Feb 18]. Available from: https:\/\/store.samhsa.gov\/product\/Federal-Guidelines-for-Opioid-Treatment-Programs\/PEP15-FEDGUIDEOTP."},{"issue":"2","key":"313_CR28","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1080\/08897077.2019.1572052","volume":"40","author":"M Doernberg","year":"2019","unstructured":"Doernberg M, Krawczyk N, Agus D, Fingerhood MI. Demystifying buprenorphine misuse: Has fear of diversion gotten in the way of addressing the opioid crisis?. Subst Abuse. 2019;40(2):148\u201353. https:\/\/doi.org\/10.1080\/08897077.2019.1572052.","journal-title":"Subst Abuse"},{"key":"313_CR29","unstructured":"SAMHSA. MAT inside correctional facilities: addressing medication diversion | SAMHSA Publications and Digital Products. Rockville MD. 2019. https:\/\/store.samhsa.gov\/product\/mat-inside-correctional-facilities-addressing-medication-diversion\/PEP19-MAT-CORRECTIONS. Accessed 18 Feb 2021."},{"key":"313_CR30","unstructured":"Substance Abuse and Mental Health Services Administration. FAQs: Provision of methadone and buprenorphine for the treatment of Opioid Use Disorder in the COVID-19. 2020. pp. 5\u20137. https:\/\/www.samhsa.gov\/sites\/default\/files\/otp-guidance-20200316.pdf. Accessed 9 Sept 2020."},{"key":"313_CR31","doi-asserted-by":"crossref","unstructured":"Blanco C, Ali MM, Beswick A, Drexler K, Hoffman C, Jones CM, et al. The American opioid epidemic in special populations: five examples. NAM Perspect. 2020 https:\/\/nam.edu\/the-american-opioid-epidemic-in-special-populations-five-examples\/. Accessed 2 Jan 2021.","DOI":"10.31478\/202010b"},{"issue":"5","key":"313_CR32","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.amjmed.2015.12.028","volume":"129","author":"SE Wakeman","year":"2016","unstructured":"Wakeman SE. Using science to battle stigma in addressing the opioid epidemic: opioid agonist therapy saves lives. Am J Med. 2016;129(5):455\u20136.","journal-title":"Am J Med"},{"issue":"14","key":"313_CR33","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1001\/jama.2014.2147","volume":"311","author":"Y Olsen","year":"2014","unstructured":"Olsen Y, Sharfstein JM. Confronting the stigma of opioid use disorder\u2014and its treatment. JAMA. 2014;311(14):1393\u20134.","journal-title":"JAMA"},{"key":"313_CR34","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/add.14180","volume":"113","author":"BP Jarvis","year":"2018","unstructured":"Jarvis BP, Holtyn AF, Subramaniam S, Tompkins DA, Oga EA, Bigelow GE, et al. Extended-release injectable naltrexone for opioid use disorder: a systematic review. Addiction. 2018;113:188\u2013209. https:\/\/doi.org\/10.1111\/add.14180.","journal-title":"Addiction."},{"key":"313_CR35","doi-asserted-by":"crossref","unstructured":"Dugosh K, Abraham A, Seymour B, McLoyd K, Chalk M, Festinger D. A systematic review on the use of psychosocial interventions in conjunction with medications for the treatment of opioid addiction. J Addict Med. 2016;10(2):1. http:\/\/content.wkhealth.com\/linkback\/openurl?sid=WKPTLP:landingpage&an=01271255-900000000-99646.","DOI":"10.1097\/ADM.0000000000000193"},{"key":"313_CR36","doi-asserted-by":"publisher","first-page":"e0244401","DOI":"10.1371\/journal.pone.0244401","volume":"15","author":"D Rice","year":"2020","unstructured":"Rice D, Corace K, Wolfe D, Esmaeilisaraji L, Michaud A, Grima A, et al. Evaluating comparative effectiveness of psychosocial interventions adjunctive to opioid agonist therapy for opioid use disorder: a systematic review with network meta-analyses. PLoS ONE. 2020;15:e0244401. https:\/\/doi.org\/10.1371\/journal.pone.0244401.","journal-title":"PLoS ONE"},{"issue":"3","key":"313_CR37","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1080\/10550887.2012.694599","volume":"31","author":"JS Woods","year":"2012","unstructured":"Woods JS, Joseph H. Reducing stigma through education to enhance medication-assisted recovery. J Addict Dis. 2012;31(3):226\u201335. https:\/\/doi.org\/10.1080\/10550887.2012.694599.","journal-title":"J Addict Dis"},{"key":"313_CR38","unstructured":"Fighting Opioid Addiction Inside the Denver Jail. | Denver Health.\u00a0https:\/\/www.denverhealth.org\/news\/2020\/01\/fighting-opioid-addiction-inside-the-denver-jail.\u00a0Accessed 22 Feb 2021."},{"key":"313_CR39","unstructured":"How Treatment for Opioid Use Disorder Is Evolving in Philadelphias Jails. | The Pew Charitable Trusts.\u00a0https:\/\/www.pewtrusts.org\/en\/research-and-analysis\/articles\/2019\/06\/04\/how-treatment-for-opioid-use-disorder-is-evolving-in-philadelphias-jails.\u00a0Accessed 22 Feb 2021."},{"key":"313_CR40","unstructured":"Festinger D, Dugosh K. Pre-arrest diversion programs: a systematic review. In: Proceedings from APHA 2019. 2019.\u00a0https:\/\/apha.confex.com\/apha\/2019\/meetingapi.cgi\/Paper\/443504?filename=2019_Abstract443504.html&template=Word.\u00a0Accessed 31 Jan 2021."},{"issue":"46","key":"313_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/adaw.32905","volume":"32","author":"A Knopf","year":"2020","unstructured":"Knopf A. Drug decriminalization measure in Oregon would not increase treatment funding. Alcohol Drug Abuse Wkly. 2020;32(46):1\u20133. https:\/\/doi.org\/10.1002\/adaw.32905.","journal-title":"Alcohol Drug Abuse Wkly"},{"key":"313_CR42","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1056\/NEJMp1604223","volume":"375","author":"AR Williams","year":"2016","unstructured":"Williams AR, Bisaga A. From AIDS to opioids\u2014How to combat an epidemic. N Engl J Med. 2016;375:813\u20135.","journal-title":"N Engl J Med."},{"key":"313_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jsat.2019.05.002","volume":"103","author":"N Krawczyk","year":"2019","unstructured":"Krawczyk N, Buresh M, Gordon MSMS, Blue TR, Fingerhood MIMI, Agus D. Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: addressing a critical care gap. J Subst Abuse Treat. 2019;103:1\u20138.","journal-title":"J Subst Abuse Treat"},{"issue":"3","key":"313_CR44","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1001\/jamapsychiatry.2018.3685","volume":"76","author":"K Fiscella","year":"2019","unstructured":"Fiscella K, Wakeman SE, Beletsky L. Buprenorphine deregulation and mainstreaming treatment for opioid use disorder: X the X Waiver. JAMA Psychiatry. 2019;76(3):229\u201330.","journal-title":"JAMA Psychiatry"},{"key":"313_CR45","doi-asserted-by":"publisher","first-page":"102905","DOI":"10.1016\/j.drugpo.2020.102905","volume":"93","author":"CS Davis","year":"2020","unstructured":"Davis CS, Samuels EA. Continuing increased access to buprenorphine in the United States via telemedicine after COVID-19. Int J Drug Policy. 2020;93:102905.","journal-title":"Int J Drug Policy"},{"key":"313_CR46","doi-asserted-by":"publisher","DOI":"10.1377\/hblog20200910.498716\/full\/","author":"U Kharti","year":"2020","unstructured":"Kharti U, Davis CS, Krawczyk N, Lynch M, Berk J, Samuels EA. These key telehealth policy changes would improve buprenorphine access while advancing health equity. Health Aff Blog. 2020. https:\/\/doi.org\/10.1377\/hblog20200910.498716\/full\/.","journal-title":"Health Aff Blog"},{"key":"313_CR47","unstructured":"Senators Markey and Paul Introduce Bipartisan Legislation to Modernize. Improve methadone treatment amid skyrocketing opioid overdoses and deaths. 2022.\u00a0https:\/\/www.markey.senate.gov\/news\/press-releases\/senators-markey-and-paul-introduce-bipartisan-legislation-to-modernize-improve-methadone-treatment-amid-skyrocketing-opioid-overdoses-and-deaths.\u00a0Accessed 23\u00a0Feb 2022."},{"key":"313_CR48","unstructured":"States Reporting Corrections-Related Medicaid Enrollment Policies In Place for Prisons. or Jails | KFF.\u00a0https:\/\/www.kff.org\/medicaid\/state-indicator\/states-reporting-corrections-related-medicaid-enrollment-policies-in-place-for-prisons-or-jails\/?currentTimeframe=0&sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D. https:\/\/www.baldwin.senate.gov\/press-releases\/medicaid-reentry-act. Accessed 22\u00a0Feb 2021."},{"key":"313_CR49","doi-asserted-by":"publisher","first-page":"108161","DOI":"10.1016\/j.jsat.2020.108161","volume":"121","author":"A Duncan","year":"2021","unstructured":"Duncan A, Sanders N, Schiff M, Winkelman TNA. Adaptations to jail-based buprenorphine treatment during the COVID-19 pandemic. J Subst Abuse Treat. 2021;121:108161.","journal-title":"J Subst Abuse Treat"},{"key":"313_CR50","unstructured":"State Waivers List. | Medicaid. https:\/\/www.medicaid.gov\/medicaid\/section-1115-demo\/demonstration-and-waiver-list\/index.html?search_api_fulltext=utah&items_per_page=10#content. Accessed 22\u00a0Feb 2021."}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-022-00313-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-022-00313-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-022-00313-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T14:11:05Z","timestamp":1654179065000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-022-00313-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,2]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["313"],"URL":"https:\/\/doi.org\/10.1186\/s13722-022-00313-6","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,2]]},"assertion":[{"value":"22 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All survey and interview participants consented to have information from their responses shared in this research article. The [<i>Johns Hopkins Bloomberg School of Public Health<\/i>] Institutional Review Board approved this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30"}}